DOCSLIB.ORG

EMERGING THREAT REPORT Fourth Quarter 2020 Special Testing and Research Laboratory

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EMERGING THREAT REPORT Fourth Quarter 2020 Special Testing and Research Laboratory Drug Enforcement Administration EMERGING THREAT REPORT Fourth Quarter 2020 Special Testing and Research Laboratory The Special Testing and Research Laboratory’s Emerging Trends Pro- by DEA. This data is a quarterly snapshot of the new psychoactive An identification is made when authenticated reference material is avail- gram compiled the data for this report through a query of archived substance market in the United States. able for comparison. When reference material is not available, the drug seizure and analysis information from drug evidence analyzed by the evidence is identified as “inconclusive.” A single unit of drug evidence The term new psychoactive substance (NPS) describes a recently emerged drug Drug Enforcement Administration’s laboratory system. This data is may have multiple sub-units. For the purposes of this document, each that may pose a public health threat. This includes synthetic cannabinoids, representative of drug evidence seized and analyzed in the date rang- unit of drug evidence counts as one identification regardless of the num- substituted cathinones, phenethylamines, opioids, tryptamines, benzodiaze- es annotated. This is not a comprehensive list of all new psychoactive ber of sub-units. Some seized drug evidence contains more than one pines, and a variety of other chemical classes. Due to the increase in seizures substances and is not representative of all evidence analyzed active ingredient; therefore, more than one identification can be made over the last several years, fentanyl is also included in this report. for a single unit. SYNTHETIC CANNABINOIDS OPIOIDS/ANALGESICS CATHINONES THERE WERE 8 SYNTHETIC CANNABINOID IDENTIFICATIONS IN THERE WERE IDENTIFICATIONS OF FENTANYL, FENTANYL-RELATED THERE WERE CATHINONE IDENTIFICATIONS THIS REPORTING THE FOURTH QUARTER OF CY2020. MDMB-4EN-PINACA WAS THE 483 13 MOST REPORTED SYNTHETIC CANNABINOID ACCOUNTING FOR COMPOUNDS, AND OTHER NOVEL OPIOIDS. FENTANYL ACCOUNTED FOR PERIOD. EUTYLONE WAS THE MOST REPORTED CATHINONE, 63% OF THE IDENTIFICATIONS. APPROXIMATELY 92% OF THE OPIOID IDENTIFICATIONS. OF THE ACCOUNTING FOR APPROXIMATELY 85% OF THE IDENTIFICATIONS. No new cannabinoids were 442 IDENTIFICATIONS, FENTANYL WAS FOUND AS THE ONLY CON- 4F-MDMB-BUTINACA 1 reported this quarter. 4Cl-N,N-Dimethylcathinone 1 No new cathinones were TROLLED SUBSTANCE IN 62% OF THE IDENTIFICATIONS AND WITH HER- reported this quarter. OIN IN APPROXIMATELY 20% OF THE IDENTIFICATIONS. 5F-MDMB-PICA 3,4-Methylenedioxy-N- 2 1 benzylcathinone Valeryl Fentanyl 1 MDMB-4en-PINACA 5 Eutylone 11 Despropionyl p-Fluorofentanyl 1 No new opioids were reported for the first time this quarter. BENZODIAZEPINES Brorphine 1 OTHER THERE WERE 55 IDENTIFICATIONS OF NPS BENZODIAZE- p-Fluorofentanyl 2 PINES. ETIZOLAM WAS THE MOST REPORTED BENZODIAZEPINE The “other” category includes substances that could not be ACCOUNTING FOR 51% OF THE IDENTIFICATIONS. Acetylfentanyl 2 confirmed, psychoactive plants, PCP related substances, benzofurans, hallucinogens, tryptamines, and amphetamines. Deschloroetizolam 1 4-ANPP 34 No new benzodiazepines were THERE WERE 6 IDENTIFICATIONS CATEGORIZED AS INCONCLUSIVE Adinazolam 1 reported for the first time this Fentanyl 442 DURING THIS REPORTING PERIOD. quarter. Flubromazolam 6 Clonazolam 8 Questions about this data are welcome and may be directed Flualprazolam 11 to the DEA Emerging Trends Program at 703-668-3300 or [email protected] Etizolam 28 DEA PRB 2021-17a .
Load more

Recommended publications
  • The Misuse of Benzodiazepines Among High-Risk Opioid Users in Europe
    EMBARGO — 7 JUNE 7. 6. 2018 UPDATED 11:30 Central European Time/CET (10:30 Western European Time/WET/Lisbon) Proof - 28 May 2018 not for circulation PERSPECTIVES ON DRUGS The misuse of benzodiazepines among high-risk opioid users in Europe Benzodiazepines are a widely prescribed I Introduction group of medicines with a range of clinical uses that include treating Benzodiazepines have a range of clinical uses and are among the most commonly prescribed medicines globally. anxiety, insomnia and managing alcohol They are useful in the short-term treatment of anxiety and withdrawal. This group of medicines is insomnia, and in managing alcohol withdrawal (Medicines often misused by high-risk opioid users, and Healthcare Products Regulatory Agency, 2015). Like all medicines, benzodiazepines can produce side effects. They and this is associated with considerable may also be misused, which we define as use without a morbidity and mortality. This paper prescription from a medical practitioner or, if prescribed, when describes the impact of benzodiazepines they are used outside accepted medical practice or guidelines. misuse on the health and treatment of While the misuse of benzodiazepines has been identified high-risk opioid users. as a concern for large groups in the general population, for example, among elderly people and women, this analysis focuses specifically on misuse among high-risk opioid users (1), a group of people among whom these medicines have been linked with severe treatment challenges and implicated in considerable numbers of drug-related deaths. It is important to stress that much benzodiazepine prescribing to high-risk drug users is done with legitimate therapeutic aims in mind.
    [Show full text]
  • 1 'New/Designer Benzodiazepines'
    1 ‘New/Designer Benzodiazepines’: an analysis of the literature and psychonauts’ trip reports 2 Laura Orsolini*1,2,3, John M. Corkery1, Stefania Chiappini1, Amira Guirguis1, Alessandro Vento4,5,6,7, 3 Domenico De Berardis3,8,9, Duccio Papanti1, and Fabrizio Schifano1 4 5 1 Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical 6 Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK. 7 2 Neomesia Mental Health, Villa Jolanda Hospital, Jesi, Italy. 8 3 Polyedra, Teramo, Italy. 9 4 NESMOS Department (Neurosciences, Mental Health and Sensory Organs), Sapienza University – Rome, School of 10 Medicine and Psychology; Sant’Andrea Hospital, Rome, Italy 11 5 School of psychology - G. Marconi Telematic University, Rome, Italy 12 6 Addictions Observatory (ODDPSS), Rome, Italy 13 7 Mental Health Department - ASL Roma 2, Rome, Italy 14 8 Department of Neuroscience, Imaging and Clinical Science, Chair of Psychiatry, University of “G. D’Annunzio”, Chieti, 15 Italy. 16 9 NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, ASL 4 17 Teramo, Italy. 18 19 Corresponding author: 20 Laura Orsolini, Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life 21 and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK; Villa Jolanda Hospital, Neomesia 22 Mental Health, Villa Jolanda, Italy; Polyedra, Teramo, Italy; E-mail address: [email protected]. Tel.: (+39) 392 23 3244643. 24 25 Conflicts of Interest 26 The authors declare that this research was conducted in the absence of any commercial or financial relationships 27 that could be construed as a potential conflict of interest.
    [Show full text]
  • The Emergence of New Psychoactive Substance (NPS) Benzodiazepines
    Issue: Ir Med J; Vol 112; No. 7; P970 The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS S. Mc Namara, S. Stokes, J. Nolan HSE National Drug Treatment Centre Abstract Benzodiazepines have a wide range of clinical uses being among the most commonly prescribed medicines globally. The EU Early Warning System on new psychoactive substances (NPS) has over recent years detected new illicit benzodiazepines in Europe’s drug market1. Additional reference standards were obtained and a multi-residue LC- MS method was developed to test for 31 benzodiazepines or metabolites in urine including some new benzodiazepines which have been classified as New Psychoactive Substances (NPS) which comprise a range of substances, including synthetic cannabinoids, opioids, cathinones and benzodiazepines not covered by international drug controls. 200 urine samples from patients attending the HSE National Drug Treatment Centre (NDTC) who are monitored on a regular basis for drug and alcohol use and which tested positive for benzodiazepine class drugs by immunoassay screening were subjected to confirmatory analysis to determine what Benzodiazepine drugs were present and to see if etizolam or other new benzodiazepines are being used in the addiction population currently. Benzodiazepine prescription and use is common in the addiction population. Of significance we found evidence of consumption of an illicit new psychoactive benzodiazepine, Etizolam. Introduction Benzodiazepines are useful in the short-term treatment of anxiety and insomnia, and in managing alcohol withdrawal. 1 According to the EMCDDA report on the misuse of benzodiazepines among high-risk opioid users in Europe1, benzodiazepines, especially when injected, can prolong the intensity and duration of opioid effects.
    [Show full text]
  • (2) Patent Application Publication (10) Pub. No.: US 2017/0020885 A1 Hsu (43) Pub
    US 20170020885A1 (19) United States (2) Patent Application Publication (10) Pub. No.: US 2017/0020885 A1 Hsu (43) Pub. Date: Jan. 26, 2017 (54) COMPOSITION COMPRISING A (52) U.S. CI. THERAPEUTIC AGENT AND A CPC ......... A61K 31/5377 (2013.01); A61K 9/0053 RESPIRATORY STIMULANT AND (2013.01); A61K 31/485 (2013.01); A61 K METHODS FOR THE USE THEREOF 9/5073 (2013.01); A61K 9/5047 (2013.01): A61K 45/06 (2013.01); A61K 9/0019 (71) Applicant: John Hsu, Rowland Heights, CA (US) (2013.01); A61K 9/209 (2013.01) (72) Inventor: John Hsu, Rowland Heights, CA (US) (57) ABSTRACT (21) Appl. No.: 15/214,421 (22) Filed: Jul. 19, 2016 The present disclosure provides a safe method for anesthesia or the treatment of pain by safely administering an amount Related U.S. Application Data of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure (60) Provisional application No. 62/195,769, filed on Jul. provides a pharmaceutical composition comprising a thera 22, 2015. peutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory Publication Classification suppressants by combining a chemoreceptor respiratory (51) Int. Cl. stimulant with an opioid receptor agonist or other respira A6 IK 31/5377 (2006.01) tory-depressing drug. The combination of the two chemical A6 IK 9/24 (2006.01) agents, that is, the therapeutic agent and the respiratory A6 IK 9/50 (2006.01) stimulant, may be herein described as the “drugs.” The A6 IK 45/06 (2006.01) present compositions may be used to treat acute and chronic A6 IK 9/00 (2006.01) pain, sleep apnea, and other conditions, leaving only non A6 IK 31/485 (2006.01) lethal side effects.
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • NMS Labs Demo Report
    NMS Labs CONFIDENTIAL 200 Welsh Road, Horsham, PA 19044-2208 Phone: (215) 657-4900 Fax: (215) 657-2972 e-mail: [email protected] Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director Demo Report Patient Name 0570B-POS Report Issued 06/19/2017 08:16 Patient ID 0570B-POS Last Report Issued 04/10/2017 13:19 Chain 17000768 Age Not Given DOB Not Given 88888 Gender Not Given Clinical Example Report Attn: IT Department Workorder 17000768 200 Welsh Road Horsham, PA 19044-2208 Received 04/10/2017 12:42 Sample ID 17000768-001 Collect Dt/Tm Not Given Matrix Blood Source Not Given Patient Name 0570B-POS Patient ID 0570B-POS Container Type Clear vial Approx Vol/Weight Not Given Receipt Notes None Entered Reporting Analysis and Comments Result Units Limit Notes 0570B Designer Benzodiazepines, Blood (Forensic) Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) Bromazepam 50 ng/mL 5.0 Bromazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries. Average peak plasma concentrations following a single 3 mg, 6 mg and 12 mg dose were reported to be 10 ng/mL at 8 hours, 83 ng/mL at 2 hours and 130 ng/mL at 1-4 hours after dosing, respectively. Chronic oral administration of 9 mg daily resulted in an steady-state plasma concentrations of 81-150 ng/mL (Average = 120 ng/mL).
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]
  • Results from Samples Checked by Toronto's Drug Checking Service
    Results from samples checked by Toronto’s drug checking service March 27 – April 9, 2021 Key findings 102 samples were checked: 70% were substances1 and 30% were used paraphernalia2 64% of the samples checked were expected3 to be fentanyl, methamphetamine, or cocaine 2% of the samples checked were known to be associated with an overdose: each sample contained fentanyl and caffeine Isotonitazene, a synthetic opioid suggested to be more potent than fentanyl, was found for the first time in an expected fentanyl substance 53% of expected3 fentanyl samples checked contained at least one of the following benzodiazepine- related drugs: desalkylflurazepam, deschloroetizolam, diazepam (Valium), etizolam, flualprazolam, flubromazolam, or meclonazepam Expected fentanyl substances 86% (19) of expected3 fentanyl substances checked4 contained fentanyl and other drugs, including: o 89% (17) contained caffeine o 63% (12) contained a benzodiazepine-related drug (!): o 47% (9) contained etizolam (!) o 16% (3) contained flualprazolam (!) o 5% (1) contained flubromazolam (!) o 32% (6) contained despropionyl fentanyl (4-ANPP) (!) o 5% (1) contained acetyl fentanyl (!) o 5% (1) contained isotonitazene (!) o 5% (1) contained phenacetin (!) o 5% (1) contained xylazine (!) Unexpected noteworthy drugs found in other expected substances 4% (2) of the remaining substances checked,4 meaning substances that weren’t expected3 to be fentanyl, contained an unexpected noteworthy drug, including: o 8% (1) of expected cocaine substances contained levamisole (!) o 8% (1) of expected cocaine substances contained phenacetin (!) Notes 1 | Substances: Two types of samples are accepted by Toronto’s drug checking service: substances and used paraphernalia. Substances could be a small amount of powder, a crushed bit of a pill, blotter, or a small amount of liquid.
    [Show full text]
  • Infographics About Synthetic Opioids
    UNODC LEADING THE INTERGRATED GLOBAL RESPONSE TO THE OPIOID CRISIS P I L L A R 1 P I L L A R 2 P I L L A R 3 P I L L A R 4 P I L L A R 5 I N T E R N A T I O N A L L A W S T R E N G T H E N I N G C O U N T E R E A R L Y W A R N I N G A N D R A T I O N A L P R E S C R I B I N G A N D S T R E N G T H E N I N G A N D S U P P O R T I N G E N F O R C E M E N T O P E R A T I O N S N A R C O T I C C A P A C I T Y A N D T R E N D A N A L Y S I S A C C E S S T O O P I O I D S P R E V E N T I O N A N D T R E A T M E N T T O D I S R U P T T R A F F I C K I N G I N T E R N A T I O N A L C O O P E R A T I O N IDENTIFYING THE MOST PREVELANT, PERSISTANT AND HARMFUL SYNTHETIC OPIOIDS U N O D C 282 90 E A R L Y TOXICOLOGY COLLABORATING IN COUNTRIES W A R N I N G INFORMED THREATS LABORATORIES A D V I S O R Y ASSESSMENTS PHARMACOLOGICAL INFORMATION L A B O R A T O R I E S A N D D A T A P O I N T S L A B O R A T O R I E S D A T A P O I N T S G L O B A L S M A R T U P D A T E S 21,400+ 120 DATA POINTS FROM COUNTRIES SYNTHETIC SEDATIVE 74 OPIOIDS HYPNOTICS REPORTED MIRRORING TO UNODC SYNTHETIC E A R L Y OPIOID TRENDS W A R N I N G A D V I S O R Y B Y 2019 131% IN THE LAST * * 3 Y E A R S Note: * 2019 data collection not finalized LIST OF SYNTHETIC OPIOIDS REPORTED TO THE UNODC EWA FROM 2009-2019 S C H E D U L E D 2-Fluorofentanyl Furanylfentanyl 4-Fluorobutyrfentanyl Methoxyacetylfentanyl 4-Fluoroisobutyrfentanyl MT-45 S C H E D U L E I Acrylfentanyl Ocfentanil ( 1 9 6 1 ) AH-7921 Tetrahydrofuranylfentanyl Butyrfentanyl U-47700 S C H E D U L E I & I V Cyclopropylfentanyl
    [Show full text]
  • Advisory Council on the Misuse of Drugs
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen NPS Committee Secretary: Linsey Urquhart 1st Floor (NE), Peel Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 1121 [email protected] Sarah Newton MP Minister for Vulnerability, Safeguarding and Countering Extremism Home Office 2 Marsham Street London SW1P 4DF 2 December 2016 Dear Minister, I am writing to recommend that you lay a temporary class drug order (TCDO) pursuant to section 2A of the Misuse of Drugs Act 1971 (MDA) for the following substances: • U-47,700 • Etizolam and other designer benzodiazepines. Please find enclosed two reports containing the Advisory Council on the Misuse of Drugs’ (ACMD) consideration of the evidence of harms on these substances. U-47,700 U-47,700 is a synthetic opioid, originally developed as a research chemical but with no legitimate use. Reportedly 7.5 times more potent than morphine it is a structural analogue of AH-7921. AH-7921 was controlled as a Class A drug in January 2015 following ACMD advice, particularly regarding its high addiction potential. The ACMD is concerned that abuse of U-47,700 has the potential for severe harms, particularly following reports from the USA of more than 80 deaths attributed to this substance and that the patterns of abuse are mirroring those of heroin. The US Drug Enforcement Administration has consequently subjected U-47,700 to temporary emergency scheduling under the Controlled Substances Act. Designer Benzodiazepines Benzodiazepines such as diazepam and chlordiazepoxide have had medical applications for more than 50 years, particularly as sedatives.
    [Show full text]
  • Poisons Standard February 2020
    POISONS STANDARD FEBRUARY 2020 I, Avi Rebera, as delegate of the Secretary to the Department of Health, make the following Poisons Standard. Dated 23 December 2019 Avi Rebera Assistant Secretary Regulatory Engagement and Planning Branch Health Products Regulation Group Department of Health Authorised Version F2020L00017 registered 10/01/2020 1. Name This instrument is the Poisons Standard February 2020. 2. New Poisons Standard This instrument consists of the Standard for the Uniform Scheduling of Medicines and Poisons No. 27 (the SUSMP 27), as set out in Schedule 2. 3. Commencement (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms. Commencement information Column 1 Column 2 Column 3 Provisions Commencement Date/Details 1. The whole of this 1 February 2020. 1 February 2020 instrument Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument. (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument. 4. Authority This instrument is made under paragraph 52D(2)(b) of the Therapeutic Goods Act 1989. 5. Repeals Each instrument that is specified in Schedule 1 to this instrument is repealed as set out in that Schedule. Authorised Version F2020L00017 registered 10/01/2020 Schedule 1—Repeals Note: See section 5.
    [Show full text]
  • Emerging Analytes of Interest for MDI
    Emerging Analytes of Interest for MDI Robert D. Johnson, PhD, F-ABFT Chief Toxicologist Tarrant County Medical Examiner’s Office September 14th, 2016 Gaithersburg, MD Overdose Deaths by Year Local 2016 Statistics • Our office had 177 drug OD deaths (January-July). 1,641 total PM cases • ~10% of PM cases were OD • ~75% are accidental • ~60% were opioid-related Novel Psychoactive Substances • NPS — newly used designer drugs ("internet drugs", "research chemicals", "legal highs") which pose similar health risks to classic illicit substances The NPS Problem Controlled drugs and NPS 600 541 500 193 400 348 NPS identified for the first time in current year 300 97 243 251 234 8 NPS identified in previous years 206 37 200 166 115 40 Psychotropic substances (1971 100 102 Convention) 119 Number of substances Number Narcotic drugs (1961 Convention) 0 2014 2009 2010 2011 2012 2013 2014 Internationally controlled substancesNew Psychoactive Substances (NPS) UNODC, Early Warning Advisory on NPS, 2009-2014 Designer Opioids • Opioids (Can the good old drugs be made “better”?) • Hydrocodone • Codeine • Morphine • Oxycodone • Methadone Morphine • Tramadol • Hydromorphone • Oxymorphone Fentanyl • Fentanyl Morbidity and Mortality Weekly Report (MMWR) Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014 January 1, 2016 / 64(50);1378-82 U47700 U47700 • U-47700 • Developed in the 1970’s • 8 times more potent than morphine • Readily available online • strong analgesia, sedation, euphoria • Death due to respiratory depression • Does not cross-react
    [Show full text]